Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials.

Cancer Metastasis Rev · 2010 · PMC2962795 · PMID 20830503

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.1600

boldest claim

The sentences

a strong trendP = 0.08so close (0.05 < p ≤ 0.1)

Letrozole also demonstrated a strong trend, despite the crossover, for improved OS (303 letrozole vs. 343 tamoxifen events; HR = 0.87; 95% CI, 0.75–1.02; P = 0.08).

also in 5,725 other papers

did not reach statistical significanceP = 0.16not close (p > 0.1)

OS did not reach statistical significance at this early follow-up (HR = 0.86; P = 0.16; 166 letrozole vs. 192 tamoxifen events; Table 1 ) [ 11 ].

also in 111,027 other papers

highly significantno p-value reported

The highly significant DFS, DDFS, and OS benefit led to unblinding of the trial approximately 1 year earlier than planned, when 66% of patients receiving placebo chose to switch to letrozole, while 34% elected no further treatment [ 62 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.